This activity is hosted on the site of our educational partner
You will be connecting to our educational partner, which controls its own content, practices, and other policies.
You will be connecting to our educational partner, which controls its own content, practices, and other policies.
Progress in the Reversal of Direct Oral Anticoagulants in Emergent Medical Situations
Powered by
Format
Webcast
Time to Complete
30 minutes
Released
December 21, 2017
Expires
December 21, 2018
Maximum Credits
0.50 / AMA PRA Category 1 CreditsTM
Accredited Provider
Sponsored by the Academy for Continued Healthcare Learning.
Commercial Supporter
Supported by an educational grant from Portola Pharmaceuticals, Inc.
Program Description
In this activity, a three-faculty panel of experts discuss clinical situations with emergent needs for direct oral anticoagulant (DOAC) reversal. Faculty are featured via a video-recorded conference, complete with an accompanying PowerPoint presentation. This virtual forum provides an objective, non-judgmental review of adverse DOAC outcomes and systematic process changes regarding situations where DOAC reversal is warranted.
Clinicians require comprehensive knowledge of available and emerging DOAC reversal agents to appropriately apply them in emergent clinical situations. The goal for this activity is to guide clinical decisions, ranging from application of reversal approaches to resumption of DOAC therapy and timing after a patient experiences bleeding or thromboembolism.
Clinicians require comprehensive knowledge of available and emerging DOAC reversal agents to appropriately apply them in emergent clinical situations. The goal for this activity is to guide clinical decisions, ranging from application of reversal approaches to resumption of DOAC therapy and timing after a patient experiences bleeding or thromboembolism.
Intended Audience
The activity is intended for hospitalists, cardiologists, primary care physicians, nurses, and other clinicians who manage anticoagulation.
Educational Objectives
Upon completion of this activity, participants will be able to:
- Outline current approaches and challenges to management of bleeding in patients receiving DOACs
- Compare and contrast available and emerging reversal agents for DOACs, including their mechanisms of action and available data
- Discuss approaches to DOAC reversal across diverse patient populations
Conflict Of Interest Disclosure Policy
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
Faculty
Christian T. Ruff, MD, MPH (Chair)
Assistant Professor of Medicine, Harvard Medical School
Associate Physician, Brigham and Women's Hospital
Boston, MA
Dr. Ruff discloses the following:
Consultant: Bayer AG, Boehringer Ingelheim GmbH, Daiichi Sankyo, Portola Pharmaceuticals, Inc., Janssen Pharmaceuticals
Grants/Research Support: Daiichi Sankyo
Elaine Hylek, MD, MPH
Professor of Medicine, Boston University School of Medicine
Medical Director - Thrombosis Clinic and Anticoagulation Service, Boston Medical Center
Boston, MA
Dr. Hylek discloses the following:
Consultant: Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Daiichi Sankyo, Janssen Pharmaceuticals, Medtronic, Pfizer Inc., Portola Pharmaceuticals, Inc.
Scientific Symposia: Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., DOASENSE GmbH, Pfizer Inc.
Bryan Kluck, DO
Cardiologist
Lehigh Valley Health Network
Allentown, PA
Dr. Kluck discloses the following:
Speakers Bureau: Janssen Pharmaceuticals, Boehringer Ingelheim GmbH
Assistant Professor of Medicine, Harvard Medical School
Associate Physician, Brigham and Women's Hospital
Boston, MA
Dr. Ruff discloses the following:
Consultant: Bayer AG, Boehringer Ingelheim GmbH, Daiichi Sankyo, Portola Pharmaceuticals, Inc., Janssen Pharmaceuticals
Grants/Research Support: Daiichi Sankyo
Elaine Hylek, MD, MPH
Professor of Medicine, Boston University School of Medicine
Medical Director - Thrombosis Clinic and Anticoagulation Service, Boston Medical Center
Boston, MA
Dr. Hylek discloses the following:
Consultant: Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Daiichi Sankyo, Janssen Pharmaceuticals, Medtronic, Pfizer Inc., Portola Pharmaceuticals, Inc.
Scientific Symposia: Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., DOASENSE GmbH, Pfizer Inc.
Bryan Kluck, DO
Cardiologist
Lehigh Valley Health Network
Allentown, PA
Dr. Kluck discloses the following:
Speakers Bureau: Janssen Pharmaceuticals, Boehringer Ingelheim GmbH
Staff Disclosures
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Credit
0.50
Type
AMA PRA Category 1 Credit(s)TM
Accreditation Statement
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug Use: Agents under investigation for reversal
Discussion of Off-Label, Investigational, or Experimental Drug Use: Agents under investigation for reversal
Disclaimer
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
Instructions
This activity will take 30 minutes to complete. To obtain credit, a score of 66% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact:
Alicia Graf
agraf@achlcme.org
If you have any questions relating to the accreditation of this activity, please contact:
Alicia Graf
agraf@achlcme.org
Privacy Policy
SYSTEM REQUIREMENTS
Hardware and Software Requirements
- A computer with an internet connection
- Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
- Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Sponsored Links